AMYT.L Share News (AMYT)
AMYT Share
AMYT Share
AMYT Share
AMYT Share
AMYT
AMYT Share
AMYT Broker
AMYT Directors
AMYT Financial
AMYT
AMYT Short
AMYT
LONDON (Alliance News) - Biotechnology firm Redx Pharma PLC on Thursday said it has changed the lease agreement at its Alderley Park headquarters in Cheshire, England, reducing the amount of will
Read moreLONDON (Alliance News) - Amryt Pharma PLC on Thursday said it now has permission to enrol infants and children under four years old in its ongoing phase three Ease trial of AP101 in the Ease will
Read moreLONDON (Alliance News) - Amryt Pharma PLC on Monday reported positive results from two pre-clinical studies of its novel non-viral gene therapy for recessive dystrophic epidermolysis company said
Read more
(Sharecast News) - Revenue-generating orphan drug company Amryt Pharma announced the results of an unblinded interim efficacy analysis on its pivotal Phase III EASE trial for AP101 as a potential treatment for Epidermolysis Bullosa (EB) on Friday.
Read moreLONDON (Alliance News) - Amryt Pharma PLC on Friday said an independent data monitoring committee has recommended adding more patients to its phase three Ease trial of epidermolysis bullosa drug a
Read more(Sharecast News) - Orphan drug company Amryt Pharma updated the market on the global AP101 EASE Phase III clinical trial being conducted in patients with Epidermolysis Bullosa (EB) on Wednesday, reporting that the independent data monitoring committee was scheduled to meet on 21 December to review the EASE unblinded interim efficacy analysis results.
Read more(Sharecast News) - Amryt Pharma announced on Monday that it has secured am €8.4m grant from the Irish Government for three years of development of its AP103 gene therapy platform.
Read moreLONDON (Alliance News) - Amryt Pharma PLC on Monday said it has secured grant funding of EUR8.4 million over three years to develop its AP103 gene therapy platform.Amryt shares were trading
Read more(Sharecast News) - Orphan drug company Amryt Pharma has reached agreement with France's Comité économique des produits de santé (CEPS) to reimburse 'Lojuxta' (lomitapide) for the treatment of adult patients with homozygous familial hypercholesterolaemia (HoFH) in France.
Read moreLONDON (Alliance News) - Oprhan drug company Amryt Pharma PLC said Wednesday its loss narrowed in the first half of 2018 due to increased sales of its rare disease drug Lojuxta and reduced the six
Read moreLONDON (Alliance News) - Amryt Pharma PLC said Thursday that the US Food & Drug Administration has granted a rare pediatric disease designation for AP101, used for the treatment of Bullosa is
Read moreLONDON (Alliance News) - Amryt Pharma PLC said on Thursday it expects its performance for 2018 to be in line with current market expectations, following strong trading in the first half.The
Read moreLONDON (Alliance News) - Amryt Pharma PLC on Monday said its cholesterol reducing drug, Lojuxta, has been approved by the NHS in England.The pharmaceutical company, which focuses on rare in
Read moreLONDON (Alliance News) - Amryt Pharma PLC on Tuesday said it signed four distribution deals for its cholesterol disorder drug Lojuxta across the Middle East.The biopharmaceutical company it
Read moreLONDON (Alliance News) - Amryt Pharma PLC on Thursday said it has expanded its Lojuxta licence agreement with Aegerion Pharmaceuticals Inc into Russia, the Commonwealth of Independent States, and
Read more